| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Calixar–SEVERAL: investment, 202003 second financing round €2.5m |
2020-03-09 |
| AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent |
2020-03-04 |
| BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform |
2020-03-03 |
| FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund |
2020-02-25 |
| Scipio Bioscience–Financière Arbevel: investment, 202002 financing round Series A totalling €6m incl new + co-investor Financière Arbevel |
2020-02-25 |
| Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF |
2020-02-25 |
| Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures |
2020-02-25 |
| Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures |
2020-02-25 |
| Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere |
2020-02-25 |
| Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 |
2020-02-18 |
| Apexbio/Cycloud–Stilla Technologies: digital PCR technology, 202002 distribution existent in China by Apexbio/Cycloud |
2020-02-11 |
| Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement |
2020-02-11 |
| Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners |
2020-02-11 |
| Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures |
2020-02-11 |
| Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners |
2020-02-11 |
| Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France |
2020-02-11 |
| Stilla Technologies–Paris Saclay Seeds: investment, 202002 financing round Series B totalling €20m incl existing investor Paris Saclay Seed Funds |
2020-02-11 |
| Stilla Technologies–SEVERAL: investment, 202002 financing round Series B €20m with new investor TUS-Holdings alongside existing investors |
2020-02-11 |
| Stilla Technologies–TUS-Holdings: investment, 202002 financing round Series B totalling €20m incl new investor CLIIF Investment Fund of Tuspark Europe |
2020-02-11 |
| MaaT Pharma–Biocodex: investment, 202002 financing round Series B totalling €18m incl existing investor Biocodex |
2020-02-05 |
| MaaT Pharma–BPCE: investment, 202002 financing round Series B totalling €18m incl existing investor Seventure Partners |
2020-02-05 |
| MaaT Pharma–Crédit Mutuel-CIC: investment, 202002 financing round Series B totalling €18m incl existing investor Crédit Mutuel Innovation |
2020-02-05 |
| MaaT Pharma–SEVERAL: investment, 202002 financing round Series B €18m with SymBiosis + Seventure + Crédit Mutuel Innovation + Biocodex et al. |
2020-02-05 |
| MaaT Pharma–SymBiosis LLC: investment, 202002 financing round Series B totalling €18m incl new investor SymBiosis LLC |
2020-02-05 |
| MaaT Pharma–Trophic Communications: public relations, 202002 service existent by Trophic Communications |
2020-02-05 |
| Inato–SEVERAL: investment, 202002 financing round Series A $14m led by Obious Ventures + Cathay Innovation |
2020-02-04 |
| Valneva–Deerfield: credit, 202002–202601 debt financing totalling $60m + optional $25m facility from Deerfield Management + OrbiMed |
2020-02-03 |
| Valneva–OrbiMed: credit, 202002–202601 debt financing totalling $60m + optional $25m facility from Deerfield Management + OrbiMed |
2020-02-03 |
| Valneva–SEVERAL: credit, 202002–202601 debt financing $60m + optional $25m facility from Deerfield Management + OrbiMed |
2020-02-03 |
| GeNeuro–Mérieux: investment, 202001 private placement totalling €17.5m incl €7.5m from existing investor GNEH SAS now largest shareholder with 36.46% |
2020-01-31 |
| GeNeuro–SEVERAL: investment, 202001 private placement €17.5m with 5.93m new shares at €2.95/share incl existent investor GNEH SAS |
2020-01-31 |
| Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies |
2020-01-28 |
| Stilla Technologies–Coulter Partners: recruitment services, 202001 supply service placement of Khaled Bahi as CFO at Stilla Technolgies |
2020-01-28 |
| PDC*line Pharma–SEVERAL: investment, 202001 financing round Series B €13.9m with existing + new investors |
2020-01-22 |
| Seekyo–Andrew Lloyd Associates: public relations, 202001 service existent by ALA |
2020-01-20 |
| Seekyo–EU (govt): credit, 202001 EIF Investment Initiation Loan €150k |
2020-01-20 |
| Seekyo–France (govt): credit, 202001 convertible bond €250k financing from French Tech Seed Fund managed by Bpifrance |
2020-01-20 |
| Seekyo–SEVERAL: investment, 202001 seed financing round €400k from investors from three business angel networks |
2020-01-20 |
| Jeito Capital–SEVERAL: investment, 202001 closing €200m of Jeito I fund |
2020-01-15 |
| Urania Therapeutics–France (govt): credit, 202001 repayable advances €850k from Bpifrance |
2020-01-14 |
| Urania Therapeutics–France (govt): grant, 202001 subsidies €850k from Bpifrance |
2020-01-14 |
| Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters |
2020-01-13 |
| Domain Therapeutics–SEVERAL: credit, 202001 debt financing €6m fomr Bpifrance + BPALC + CIC + CEGEE |
2020-01-13 |
| Iovance–Cellectis: gene editing technology, 202001– collab + license ww excl for TILs in several cancer indications |
2020-01-12 |
| Alderaan Biotechnology–Advent France Biotechnology: investment, 202001 financing round Series A totalling €18.5m incl existing investor AFB |
2020-01-09 |
| Alderaan Biotechnology–Medicxi: investment, 202001 financing round Series A totalling €18.5m incl new investor Medicxi |
2020-01-09 |
| Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi |
2020-01-09 |
| Sanofi–Nurix Therapeutics: protein degradation drugs, 202001– collab strategic ww $55m upfront + $2.5m milestones using DELigase platform |
2020-01-09 |
| Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures |
2020-01-08 |
| Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund |
2020-01-08 |
| Eyevensys–CapDecisif: investment, 202001 financing round Series B totalling $30m incl existing + co-investor CapDecisif |
2020-01-08 |
| Eyevensys–France (govt): investment, 202001 financing round Series B totalling $30m incl existing + co-investors Bpifrance + Inserm Transfert |
2020-01-08 |
| Eyevensys–Pontifax: investment, 202001 financing round Series B totalling $30m incl existing + co-investor Pontifax |
2020-01-08 |
| Eyevensys–Quark Venture: investment, 202001 financing round Series B totalling $30m incl new + co-investor GHS Fund (Quark Venture + GF Securities) |
2020-01-08 |
| Eyevensys–RooneyPartners: public relations, 202001 service existent by RooneyPartners |
2020-01-08 |
| Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund |
2020-01-08 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis |
2020-01-06 |
| TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine |
2020-01-01 |
| Novartis–Voluntis: digital therapeutics, 201912–collab developm digital therapeutics using Theraxium Oncology platform for breast cancer |
2019-12-18 |
| Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB |
2019-12-16 |
| Voluntis–Salesforce: CRM software, 201912– collab using Salsesforce cloud + analytics s/w to implement VPS DTx prescription + reimbursement |
2019-12-16 |
| Aelis Farma–NewCap: public relations, 201912 service existent by NewCap |
2019-12-13 |
| Aelis Farma–SEVERAL: grant, 201912c research grants totalling €9m from various organisations incl US NIDA |
2019-12-13 |
| Aelis Farma–SEVERAL: investment, 201912 financing round €11m incl Region Nouvelle Aquitaine + Inserm Transfert Initiative + Bpifrance |
2019-12-13 |
| Inscripta–SEVERAL: investment, 201912 financing round Series D $125m led by Paladin Capital Group |
2019-12-10 |
| Synthorx–Sanofi: investment, 201912– acquisition $2.35b cash tender offer at $68/share ANNOUNCED |
2019-12-09 |
| ImCheck Therapeutics–Agent Capital: investment, 201912 financing round Series B totalling €48m incl new + co-investor Agent Capital |
2019-12-04 |
| ImCheck Therapeutics–Alexandria Real Estate: investment, 201912 financing round Series B totalling €48m incl new + co-investor Alexandria Venture |
2019-12-04 |
| ImCheck Therapeutics–Boehringer: investment, 201912 financing round Series B totalling €48m incl existing + co-investor BIVF |
2019-12-04 |
| ImCheck Therapeutics–Dechert: legal services, 201912 supply service Dechert LLP acted as legal counsel for €48m Series B round of ImCheck |
2019-12-04 |
| ImCheck Therapeutics–Dentons: legal services, 201912 supply service Dentons Europe acted as legal counsel for €48m Series B round of ImCheck |
2019-12-04 |
| ImCheck Therapeutics–Eurazeo: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Idinvest Partners |
2019-12-04 |
| ImCheck Therapeutics–France (govt): investment, 201912 financing round Series B totalling €48m incl co-lead investor Bpifrance InnoBio 2 + LV funds |
2019-12-04 |
| ImCheck Therapeutics–Gimv: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Gimv |
2019-12-04 |
| ImCheck Therapeutics–Kurma: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Kurma Partners |
2019-12-04 |
| ImCheck Therapeutics–Life Sciences Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor LSP |
2019-12-04 |
| ImCheck Therapeutics–Pfizer: investment, 201912 financing round Series B totalling €48m incl co-lead investor Pfizer Ventures |
2019-12-04 |
| ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures |
2019-12-04 |
| ImCheck Therapeutics–Trophic Communications: public relations, 201912 service existent IR + PR US + EU by Trophic |
2019-12-04 |
| ImCheck Therapeutics–Wellington Partners: investment, 201912 financing round Series B totalling €48m incl new + co-investor Wellington Partners |
2019-12-04 |
| Diabeloop–SEVERAL: investment, 201912 financing round Series B €22m led by Cemag Invest |
2019-12-02 |
| Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials |
2019-12-02 |
| Sanofi–Ligand: transgenic animal technology, 201912– license ww for OmniAb platform |
2019-12-02 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| Tissium–SEVERAL: investment, 201911 financing round Series B €38.75m from EIB + French investors |
2019-11-20 |
| Acticor Biotech–SEVERAL: investment, 201911 financing round Series B extension €7m led by new investorGO Capital bringing Series B to €22.3m |
2019-11-06 |
| AVCare–Acticor Biotech: investment, 201911 acquisition 100% of AVCare by Acticor Biotech |
2019-11-06 |
| Urania Therapeutics–Advent France Biotechnology: investment, 201911 seed financing round totalling €3.53m incl lead investor AFB |
2019-11-06 |
| Urania Therapeutics–Andrew Lloyd Associates: public relations, 201911 service existent by ALA |
2019-11-06 |
| Urania Therapeutics–Capital Grand Est: investment, 201911 seed financing round totalling €3.53m incl co-investor Cap Innov’Est |
2019-11-06 |
| Urania Therapeutics–Novalix: drug development services, 201911– supply of drug development services to Urania by Novalix |
2019-11-06 |
| Urania Therapeutics–SEVERAL: investment, 201911 seed financing round €3.53m led by Advent France Biotechnology + incl Cap Innov’Est |
2019-11-06 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2019.png){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
